pharma news today glp-1 obesity drugs today Market Overview: Agonists and the Market | Blog Pfizer moves forward with weight-loss

EMEA and LATAM Anti-obesity Drugs Market Europe controlled roughly 25% of the anti-obesity drugs market in 2025, yet reimbursement gatekeeping restrains volume growth

Home / Tag Archives: GLP-1 receptor agonist Tag Archives: GLP-1 receptor agonist Oral GLP-1 Therapy Without Restrictions: When Should Clinicians Choose It First

Pricing, Reimbursement and Market Access: Discusses issues related to pricing, payer restrictions, prior authorization, patient costs, lack of insurance coverage and health economic considerations

These programs typically require proof of a Medicaid denial letter, documentation of household income, and a prescription from a licensed provider

Boehringer Ingelheims Survodutide Survodutide (BI 456906), co-invented by Boehringer Ingelheim and Zealand Pharma, is an investigational glucagon/GLP-1 receptor dual agonist

Our experiment aims to clarify the mechanism of berberine promoting the secretion of GLP-1 in intestinal L cell and islet cell, activating GLP-1R and its downstream molecules through endocrine and paracrine ways, thus improving the function of islet cell and treating T2DM